Mirvetuximab Soravtansine-gynx

Am J Health Syst Pharm. 2023 Mar 21;80(7):395-397. doi: 10.1093/ajhp/zxad001.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Immunoconjugates*
  • Maytansine* / adverse effects

Substances

  • mirvetuximab soravtansine
  • Maytansine
  • Immunoconjugates
  • Antibodies, Monoclonal, Humanized